Kloma Cardoza

Kloma Cardoza

Auto-generated profile, based on publicly available information

Kloma Cardoza

Department of Biological Sciences, The University of Texas at Dallas, Richardson, USA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2026 in Cancer Research
Verified
Journal Article
Closed access
SHSarah K. Herzog
Sarah K. Herzog
JSJessica Stevens
Jessica Stevens
GGGuowei Gu
Guowei Gu
SGSandra Grimm
Sandra Grimm
KCKloma Cardoza
Kloma Cardoza
SFSuzanne A.W. Fuqua
Suzanne A.W. Fuqua
ESR1 mutations are the leading cause of endocrine therapy resistance and progression in estrogen receptor (ER)–positive metastatic breast cancer. ESR1 mutations are detected in ∼50% of patients with metastatic breast cancer, and identification of effective targeted therapeutics is critically needed. In this study, we identified enrichment of dysregulated replication stress and DNA damage responses in multiple ESR1-mutant models. Targeting the replication stress response utilizing checkpoint inhibition in combination with PARP inhibition synergistically suppressed growth, induced cell cycle arrest, and attenuated DNA replication. PARP inhibition blocked metastatic dissemination in vivo and reduced both PARP1 and ER-regulated protein expression. PARP trapping by olaparib treatment with or without endocrine therapy resulted in a significant increase in colocalized DNA-bound PARP1 and ER protein in ESR1-mutant cells, indicating ER–PARP1 coregulation in ESR1-mutant breast cancer. Long-term treatment with endocrine therapy plus the CDK4/6 inhibitor abemaciclib led to the emergence of a ESR1Y537S mutation in a cell line, which exhibited dysregulation of replication stress response, enhanced DNA damage response, and synergistic responses to inhibitors of these pathways. PARP inhibition also synergized with clinically relevant endocrine therapy in ESR1-mutant models, reducing tumor growth both ex vivo and in vivo. Together, these results identify replication stress and DNA damage responses as key dysregulated pathways in ESR1-mutant breast cancer with significant clinical potential for PARP inhibition in this metastatic breast cancer subset. Significance: ESR1-mutant breast cancer exhibits enriched replication stress and DNA damage, creating a therapeutic vulnerability to PARP inhibition in ER+ breast cancer without genomic homologous recombination defects.

13 July 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SMSubhajit Maity
Subhajit Maity
SFSami M. Frascoli
Sami M. Frascoli
AKAkshita Krishnan
Akshita Krishnan
PPPreethi Parupalli
Preethi Parupalli
KCKloma T. Cardoza
Kloma T. Cardoza
PJPurna A. Joshi
Purna A. Joshi
Stromal-epithelial interactions underlie fundamental tissue morphogenesis in normal development, tissue regeneration, and cancer. Peripheral nerves are increasingly implicated as important stromal drivers of normal and malignant epithelial tissue biology. In the mammary gland, epithelial cell fate is highly dependent on stromal cues during distinct stages of postnatal growth, which are triggered by ovarian sex hormones estrogen and progesterone. However, the effects of sex hormones on peripheral nerves in the postnatal mammary gland are largely unknown. Here, we uncover extensive changes in peripheral sympathetic innervation in the mammary stromal microenvironment during puberty and pregnancy, which are periods of active postnatal mammary epithelial growth. We find that sex hormones induce sympathetic axonal branching through an intricate hormone-epithelial-nerve cross-talk. Specifically, estrogen and progesterone stimulate the expression of brain-derived neurotrophic factor (BDNF) in mammary hormone receptor-expressing luminal epithelial cells, which acts on Tropomyosin receptor kinase B (TrkB)-expressing sympathetic nerves to activate BDNF-TrkB signaling. Our findings illustrate a previously unrecognized capacity of hormone-sensing epithelial cells to modulate sympathetic innervation, providing a framework for understanding nerve dynamics during tissue regeneration and cancer.

2 April 2026
Verified
Other
Open access
SHSarah K. Herzog
Sarah K. Herzog
JSJessica Stevens
Jessica Stevens
GGGuowei Gu
Guowei Gu
SGSandra Grimm
Sandra Grimm
KCKloma Cardoza
Kloma Cardoza
SFSuzanne A.W. Fuqua
Suzanne A.W. Fuqua
ESR1 mutations are the leading cause of endocrine therapy resistance and progression in estrogen receptor (ER)–positive metastatic breast cancer. ESR1 mutations are detected in ∼50% of patients with metastatic breast cancer, and identification of effective targeted therapeutics is critically needed. In this study, we identified enrichment of dysregulated replication stress and DNA damage responses in multiple ESR1-mutant models. Targeting the replication stress response utilizing checkpoint inhibition in combination with PARP inhibition synergistically suppressed growth, induced cell cycle arrest, and attenuated DNA replication. PARP inhibition blocked metastatic dissemination in vivo and reduced both PARP1 and ER-regulated protein expression. PARP trapping by olaparib treatment with or without endocrine therapy resulted in a significant increase in colocalized DNA-bound PARP1 and ER protein in ESR1-mutant cells, indicating ER–PARP1 coregulation in ESR1-mutant breast cancer. Long-term treatment with endocrine therapy plus the CDK4/6 inhibitor abemaciclib led to the emergence of a ESR1Y537S mutation in a cell line, which exhibited dysregulation of replication stress response, enhanced DNA damage response, and synergistic responses to inhibitors of these pathways. PARP inhibition also synergized with clinically relevant endocrine therapy in ESR1-mutant models, reducing tumor growth both ex vivo and in vivo. Together, these results identify replication stress and DNA damage responses as key dysregulated pathways in ESR1-mutant breast cancer with significant clinical potential for PARP inhibition in this metastatic breast cancer subset.Significance:ESR1-mutant breast cancer exhibits enriched replication stress and DNA damage, creating a therapeutic vulnerability to PARP inhibition in ER+ breast cancer without genomic homologous recombination defects.

2 April 2026
Verified
Other
Open access
SHSarah K. Herzog
Sarah K. Herzog
JSJessica Stevens
Jessica Stevens
GGGuowei Gu
Guowei Gu
SGSandra Grimm
Sandra Grimm
KCKloma Cardoza
Kloma Cardoza
SFSuzanne A.W. Fuqua
Suzanne A.W. Fuqua
Evaluation of CDK4/6 inhibitor cross-resistance in FulvR and AbemaR breast cancer models a. MTT growth assay of FulvR vs parental MCF-7 cells treated with indicated concentrations of Abema or b. CDK4/6 inhibitors ribociclib (1.5 µM), palbociclib (200 nM) or Abema (500 nM). c. MTT growth assay of AbemaR versus parental MCF-7 cells, d. F+A versus parental MCF-7 cells, e. FulvR versus parental ZR75-1 cells, or f. AbemaR versus parental ZR75-1 cells treated with ribociclib (1.5 µM), palbociclib (200 nM) or Abema (500 nM). Bars represent mean+standard deviation of %viability normalized to untreated controls within each cell line. All MTT assays were performed in minimum technical quadruplicate at all concentrations in all cell lines. Cell lines are labeled by biological replicate. Statistical analysis was performed utilizing 2-way ANOVA corrected for multiple comparisons comparing all resistant cell lines to parental controls. *p-val<0.05, **p-val<0.01, ***p-val<0.001, ****p-val<0.0001.

2 April 2026
Verified
Other
Open access
SHSarah K. Herzog
Sarah K. Herzog
JSJessica Stevens
Jessica Stevens
GGGuowei Gu
Guowei Gu
SGSandra Grimm
Sandra Grimm
KCKloma Cardoza
Kloma Cardoza
SFSuzanne A.W. Fuqua
Suzanne A.W. Fuqua
DdPCR confirmation and enrichment of the Y537S ESR1 mutation in F+A cells, and WT ER in AbemaR and FulvR cells Scatter plot and quantitation of ddPCR droplets for Y537S or WT ESR1 after a-b. 8 months or c-d. 12 months of treatment with Fulv+Abema confirmed by ddPCR in F+A cells. e. Scatter plot and f. quantitation of ddPCR droplets for Y537S and WT alleles in the MCF-7 AbemaR cell line after 17 months of treatment. g. Scatter plot and h. quantitation of ddPCR droplets for Y537S and WT alleles in the MCF-7 FulvR cell line after 13 months of treatment. i. Scatter plot and j. quantitation of ddPCR droplets for Y537S and WT alleles in the ZR75-1 AbemaR cell line after 8 months of treatment. k. Scatter plot and l. quantitation of ddPCR droplets for Y537S and WT alleles in the ZR75-1 FulvR cell line after 8 months of treatment. Positive mutations were detected at a threshold of 3 per 1000 droplets.

2 April 2026
Verified
Other
Open access
SHSarah K. Herzog
Sarah K. Herzog
JSJessica Stevens
Jessica Stevens
GGGuowei Gu
Guowei Gu
SGSandra Grimm
Sandra Grimm
KCKloma Cardoza
Kloma Cardoza
SFSuzanne A.W. Fuqua
Suzanne A.W. Fuqua
Individual tumor growth curves of WHIM20 PDX in vivo a. Primary tumor growth of individual WHIM20 PDX tumors from first measurable tumor volume groups by -E2 b. Olap, c. Fulv, and d. Fulv+Olap treatments.